Research Center for Genetic Engineering, National Research and Innovation Agency (BRIN), Bogor, 16911, West Java, Indonesia.
Present address: The International Institute of Molecular Mechanisms and Machines, Polish Academy of Sciences, Warsaw, Poland.
Asian Pac J Cancer Prev. 2022 Jul 1;23(7):2243-2253. doi: 10.31557/APJCP.2022.23.7.2243.
Human Papillomavirus type 52 (HPV 52) is considered one of the threatening HPV types inducing cervical cancer worldwide. This study was conducted to address strategies of an effective vaccine against cervical cancer using computational approaches immuno-informatics and molecular docking.
Major capsid protein L1 and L2 HPV 52 (L1 and L2 HPV 52) sequences were investigated by multiple analyses including B and T cell epitope, toxicity, allergenicity, Immunogenicity, epitope conservancy, population coverage, and molecular docking.
L1 and L2 HPV 52 showed a conserved sequence among amino acid levels. Q307K, S383D/N, and D473E are found as major mutations in L1, while mutations in L2 are S122T, Q247H, L247S, and E365D. Multiple epitopes were identified and elicited strong immune responses against cross types of HPV in various HLA populations. To enhance vaccine effectiveness that allows having cross-protection over HPV types, N terminus HPV L2 was analyzed suggesting multi-candidates chimeric L1/L2 vaccine design.
This study shed a light on a useful pipeline with robust analysis for effective vaccine production.
人乳头瘤病毒 52 型（HPV 52）被认为是全球导致宫颈癌的威胁性 HPV 类型之一。本研究采用计算免疫信息学和分子对接方法，探讨针对宫颈癌的有效疫苗策略。
对 HPV 52 的主要衣壳蛋白 L1 和 L2（L1 和 L2 HPV 52）序列进行了多项分析，包括 B 细胞和 T 细胞表位、毒性、过敏性、免疫原性、表位保守性、人群覆盖率和分子对接。
L1 和 L2 HPV 52 在氨基酸水平上显示出保守的序列。Q307K、S383D/N 和 D473E 是 L1 中的主要突变，而 L2 中的突变是 S122T、Q247H、L247S 和 E365D。鉴定出多个表位，在各种 HLA 人群中针对 HPV 交叉型产生强烈的免疫反应。为了提高允许对 HPV 类型产生交叉保护的疫苗效力，对 HPV L2 的 N 端进行了分析，提出了多候选嵌合 L1/L2 疫苗设计。
本研究为有效疫苗的生产提供了一种有用的、具有强大分析能力的流水线。
